Achilles Therapeutics PLC

Achilles Therapeutics Plc is a biopharmaceutical company engages in developing transformative precision T-cell therapies to treat multiple types of solid tumors. It focuses on researching, developing and commercializing potentially novel cancer immunotherapies targeting clonal neoantigens. The company was founded by Karl Peggs, Sergio Quezada, Mark Lowdell and Charles Swanton in November 2020 and is headquartered in London, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Achilles Therapeutics Plc is a biopharmaceutical company engaged in developing transformative precision T-cell therapies to treat multiple types of solid tumors. It focuses on researching, developing and commercializing potentially novel cancer immunotherapies targeting clonal neoantigens. The company was founded by Karl Peggs, Sergio Quezada, Mark Lowdell and Charles Swanton in November 2020 and is headquartered in London, the United Kingdom.

- Early proof-of-concept data support durable clinical benefit including confirmed partial response and stable disease in heavily pre-treated patients with advanced NSCLC -

Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022

- Durable partial response (PR) and stable disease (SD) achieved in heavily pre-treated non-small cell lung cancer (NSCLC) patients dosed with cNeT monotherapy -

Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022

- US patent is for an immunotherapy targeting clonal neoantigens identified by the Achilles Clonality Engine (ACE), including vaccine, antibody, and autologous T cell therapy approaches - - US patent is for an immunotherapy targeting clonal neoantigens identified by the Achilles Clonality Engine (ACE), including vaccine, antibody, and autologous T cell therapy approaches -

Achilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary Method

- Interim update from the ongoing Phase I/IIa trials in advanced NSCLC (CHIRON) and melanoma (THETIS) to be presented at the ESMO Immuno-Oncology Annual Congress 2022 -

Achilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

Achilles Therapeutics PLC Sponsored ADR (ACHL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Achilles Therapeutics PLC Sponsored ADR (ACHL) a New Buy Stock

Professor Swanton joins Achilles SAB member Dr. Christopher Klebanoff and Dr. John Haanen on the key opinion leader panel to discuss neoantigens as valuable immunotherapy targets

Achilles Therapeutics Co-founder Professor Charles Swanton to Participate in Expert Roundtable Highlighting Pivotal Nature of Neoantigens as Targets in Cancer Cell Therapy

- Additional clinical data from the ongoing Phase I/IIa trials in advanced NSCLC (CHIRON) and melanoma (THETIS) expected to be available in Q4 2022 -

Achilles Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

€4 million ($4.2 million) research and innovation award for consortium to develop first-in-class smart bioprocessing manufacturing platform €4 million ($4.2 million) research and innovation award for consortium to develop first-in-class smart bioprocessing manufacturing platform

Achilles Therapeutics to lead Horizon Europe-Funded Consortium to Advance Personalized Cell Therapy Manufacturing

LONDON, June 30, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the appointment of James Taylor as Chief Business Officer and Cassian Yee, MD to its Scientific Advisory Board (SAB), effective July 1, 2022.

Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board

LONDON, June 21, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that the Company was named the winner of the Pharmaceutical Industry Network Group (PING) Innovation Award. Hosted by the law firm VWV, the PING Innovation Award recognizes individuals and organizations whose innovative ideas, products, services or processes in the pharmaceuticals and life sciences sector are making a positive impact on people's lives.

Achilles Therapeutics Recognized with the 2022 PING Innovation Award

- Dosed first patient with higher-dose (Process 2) cNeT for advanced NSCLC (CHIRON) and initiated enrollment of cNeT + PD-1 inhibitor combination (THETIS Cohort B) for metastatic malignant melanoma -

Achilles Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

- THETIS Cohort B enrollment follows positive Independent Data Safety Monitoring Committee review -

Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant Melanoma

LONDON, May 04, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the appointment of Bernhard Ehmer, MD, to the Board as a Non-Executive Director. Bernhard joins Achilles with a strong track record in international R&D, regulatory and commercial activities.

Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors

– Expansion will supply clinical grade cNeT for ongoing Phase I/IIa clinical trials and support future development –

Achilles Therapeutics Announces Manufacturing Expansion in the UK and Partnership for Manufacturing in the US

Strategic Partnership to Deliver US Based Manufacturing Capacity for Novel Cell Therapy KING OF PRUSSIA, Pa. , April 12, 2022 /PRNewswire/ --The Center for Breakthrough Medicines (CBM) announced today a partnership with London-based Achilles Therapeutics plc (NASDAQ: ACHL).

The Center for Breakthrough Medicines (CBM) Strikes Multi-Year Deal with UK Cell Therapy Powerhouse

- Webcast will feature Professor Charles Swanton, TRACERx Chief Investigator and Achilles co-founder -

Achilles Therapeutics to Host KOL Webcast to Highlight TRACERx Study Presentations from the 2022 AACR Annual Meeting

LONDON, March 08, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced its participation in the 32nd Annual Oppenheimer Healthcare Conference taking place virtually March 15 - 17, 2022. Iraj Ali, Chief Executive Officer, will present an overview of the company and pipeline on Tuesday, March 15, 2022, at 8:00 am ET / 12:00 pm UK.

Achilles Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference

- Patient data from higher dose cNeT as monotherapy and cNeT in combination with checkpoint inhibitor expected in 2H 2022 -

Achilles Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Business Highlights

Internationally recognized experts bring extensive scientific and clinical research expertise in cancer immunology and immunotherapy Internationally recognized experts bring extensive scientific and clinical research expertise in cancer immunology and immunotherapy

Achilles Therapeutics Strengthens Scientific Advisory Board with Appointment of Alena Gros, Ph.D. and Ben Creelan, M.D.

LONDON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announces a business update and reflects on recent progress with its pioneering, personalized T cell therapy programs targeting clonal neoantigens known as cNeT. As the original mutations formed early in cancer's development, clonal neoantigens are protein markers that are present on all of an individual's cancer cells but are absent from healthy tissue. Achilles has developed industry-leading clonal neoantigen discovery technology using real world patient data (TRACERx) and its proprietary bioinformatics platform (PELEUS®) to enable the identification of each patient's unique clonal neoantigens. With this expertise, Achilles aims to target all of a patient's tumor cells while sparing healthy tissue, thereby delivering a true precision T cell therapy for the first time using genomic information from a tumor.

Achilles Therapeutics Provides Business Update and Outlook for 2022

LONDON, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that Iraj Ali, Chief Executive Officer, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022, at 8:15 a.m. ET.

Achilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference

LONDON, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that the Company has been added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to market open today, Monday, December 20, 2021.

Achilles Therapeutics Added to the NASDAQ Biotechnology Index

-Over 10-fold dose increase at GMP scale with VELOS™ Process 2 manufacturing-

Achilles Therapeutics Presents Positive Data at ESMO I-O Congress 2021 on High-Dose Manufacturing Process for Precision T Cell Therapies Targeting Clonal Neoantigens

Achilles Therapeutics plc (ACHL) CEO Iraj Ali on SITC & Corporate Update Call (Transcript)

- Conference call and webcast scheduled for today at 8:30am ET / 1:30pm UK - - Conference call and webcast scheduled for today at 8:30am ET / 1:30pm UK -

Achilles Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Demonstrating the Ability to Detect, Quantify and Track Patient-specific cNeT and Significant Increase in cNeT Dose from VELOS™ Process 2 Manufacturing

News for Achilles Therapeutics PLC Stock (ACHL)